OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics Corp exhibited solid financial performance with a gross margin increase of 50 basis points year-over-year, driven by lower international set sales and improved 7D placements. Additionally, the company reported a 17.3% growth in Trauma & Deformity sales, reaching $44.1 million, alongside a notable increase in EBITDA margin by 280 basis points year-over-year, indicating operational efficiency and effective cost management. The continued strong performance in core segments and anticipated revenue growth from new product introductions position OrthoPediatrics favorably for future margin improvement and cash flow enhancement.

OrthoPediatrics's stock outlook is negatively influenced by several fundamental financial challenges, including a slowdown in revenue growth to 12.2% in the third quarter of 2025 from 15.7% in the previous quarter, indicating potential sales rep attrition and unsuccessful new product launches. The company has also seen a decrease in revenue generation from newly acquired products, with a trailing twelve months performance declining to $16.0 million, down from $17.2 million in the prior quarter. Furthermore, fiscal guidance for 2025 has been lowered to $233.5 million to $234.5 million, reflecting concerns over margin improvement and cash flow amidst overall weakening performance and productivity among distributors.